CNTG Centogene N.V.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
$12.93
As of 04/13/2021 IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Diagnostics & Research
Index country: Germany
Country of incorporation: The Netherlands
IPO date: 11/07/2019
Outstanding shares: 19,861,340
Average volume: 33,159
Market cap: $247,869,523
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
CUSIP: N1976T109
ISIN: NL0014040206
Sedol: BK824K5
Valuation (See tab for details)
PE ratio: -8.31
PB ratio: 4.17
PS ratio: 2.84
Return on equity: -50.22%
Net income %: -40.65%